LYEL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.00

-100%

-2.757

-80.85%

0.00

-100%

-2.655

-26.25%

0.00

-100%

-2.900

+0.35%

Estimates Revision

Stock Price

Go Up

+145.08%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast LYEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 17.33 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

1 Sell

Hold

Current: 32.400

Low

12.00

Averages

17.33

High

20.00

Current: 32.400

Low

12.00

Averages

17.33

High

20.00

H.C. Wainwright

Neutral -> Buy

upgrade

$20 -> $45

2025-12-09

Reason

H.C. Wainwright

Price Target

$20 -> $45

2025-12-09

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Lyell Immunopharma to Buy from Neutral with a price target of $45, up from $20. The firm has "increased conviction" following the company's recent data and a key opinion leader call on colorectal cancer. Ronde-cel has established itself as the "durability leader in the CD19/CD20 CAR-T race," the analyst tells investors in a research note. H.C. Wainwright adds that its new expert feedback confirms that Lyell's existing LYL273 dataset is "already clearing the clinical high jump for success" in third and fourth lines colorectal cancer "by a wide margin."

H.C. Wainwright

Neutral

maintain

$10 -> $20

2025-11-24

Reason

H.C. Wainwright

Price Target

$10 -> $20

2025-11-24

maintain

Neutral

Reason

H.C. Wainwright raised the firm's price target on Lyell Immunopharma to $20 from $10 and keeps a Neutral rating on the shares. The firm added colorectal cancer to the company's valuation.

Lucid Capital

Christopher Liu

Buy

initiated

$20

2025-09-26

Reason

Lucid Capital

Christopher Liu

Price Target

$20

2025-09-26

initiated

Buy

Reason

Lucid Capital analyst Christopher Liu initiated coverage of Lyell Immunopharma with a Buy rating and $20 price target. Lyell is a clinical-stage biotechnology company focused on developing potentially curative cell therapies for cancer patients, the analyst tells investors in a research note. The firm sees peak sales of $2.2B by 2039 for the company's lead asset ronde-cel in diffuse large B-cell lymphoma. The market is competitive, but there is room for several assets in the space given the meaningfully large opportunity, contends Lucid.

H.C. Wainwright

Mitchell Kapoor

Neutral

upgrade

$1 -> $10

2025-06-24

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$1 -> $10

2025-06-24

upgrade

Neutral

Reason

H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Lyell Immunopharma to $10 from $1 and keeps a Neutral rating on the shares. The firm adjusted the company's model to account for the 20-for-1 reverse split earlier this month.

HC Wainwright & Co.

Mitchell Kapoor

Hold

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

2025-04-16

Reiterates

Hold

Reason

HC Wainwright & Co.

Mitchell Kapoor

Hold

Reiterates

2025-03-13

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

2025-03-13

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Lyell Immunopharma Inc (LYEL.O) is -3.47, compared to its 5-year average forward P/E of -3.59. For a more detailed relative valuation and DCF analysis to assess Lyell Immunopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.59

Current PE

-3.47

Overvalued PE

-0.65

Undervalued PE

-6.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.67

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.09

Undervalued EV/EBITDA

-5.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

404.38

Current PS

0.00

Overvalued PS

1707.39

Undervalued PS

-898.64

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LYEL News & Events

Events Timeline

No data

News

4.0

12-09Yahoo Finance

Lyell Immunopharma Stock Increases Following HC Wainwright Upgrade

4.0

12-09Benzinga

Eaton Analyst Becomes Optimistic; Check Out Tuesday's Top 5 Upgrades

9.0

12-08NASDAQ.COM

Lyell's Ronde-cel Demonstrates Long-lasting Complete Responses and Acceptable Safety in High-Risk LBCL Patients

People Also Watch

Frequently Asked Questions

What is Lyell Immunopharma Inc (LYEL) stock price today?

The current price of LYEL is 32.4 USD — it has decreased -5.98 % in the last trading day.

What is Lyell Immunopharma Inc (LYEL)'s business?

Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

What is the price predicton of LYEL Stock?

What is Lyell Immunopharma Inc (LYEL)'s revenue for the last quarter?

Lyell Immunopharma Inc revenue for the last quarter amounts to 15.00K USD, decreased -55.88 % YoY.

What is Lyell Immunopharma Inc (LYEL)'s earnings per share (EPS) for the last quarter?

Lyell Immunopharma Inc. EPS for the last quarter amounts to -2.13 USD, decreased -38.79 % YoY.

What changes have occurred in the market's expectations for Lyell Immunopharma Inc (LYEL)'s fundamentals?

The market is revising No Change the revenue expectations for LYEL for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 145.08%.

How many employees does Lyell Immunopharma Inc (LYEL). have?

Lyell Immunopharma Inc (LYEL) has 300 emplpoyees as of December 16 2025.

What is Lyell Immunopharma Inc (LYEL) market cap?

Today LYEL has the market capitalization of 688.30M USD.